Preferential inhibition of type B-MAO by new compounds, 1-[3-(dimethylamino)propyl]-5-methyl-3-phenyl-1h-indazole(Fs32) and its N-desmethylated derivative (FS97).
D000818:Animals; D000929:Antidepressive Agents, Tricyclic / Q000494:pharmacology; D001921:Brain / Q000201:enzymology*; D066298:In Vitro Techniques; D007191:Indazoles / Q000494:pharmacology*; D007700:Kinetics; D008928:Mitochondria / Q000201:enzymology*; D008996:Monoamine Oxidase Inhibitors; D009419:Nerve Tissue Proteins / Q000378:metabolism; D011720:Pyrazoles / Q000494:pharmacology*; D051381:Rats
D000929:Antidepressive Agents, Tricyclic; D007191:Indazoles; D008996:Monoamine Oxidase Inhibitors; D009419:Nerve Tissue Proteins; D011720:Pyrazoles; C020952:1-(3-(dimethylamino)propyl)-5-methyl-3- phenyl-1H-indazole; C025243:1-(3-(methylamino)-propyl)-5-methyl-3-phenyl-1H-indazole